Follow
Suneil Jain
Suneil Jain
Professor of Clinical Oncology, Queens University Belfast
Verified email at qub.ac.uk - Homepage
Title
Cited by
Cited by
Year
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
22942015
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
L Klotz, D Vesprini, P Sethukavalan, V Jethava, L Zhang, S Jain, ...
Journal of Clinical Oncology, JCO. 33(3) 272-277, 2015
13322015
Gold nanoparticles as novel agents for cancer therapy
S Jain, DG Hirst, JM O'sullivan
The British journal of radiology, 2012
12622012
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ...
The Lancet Oncology 21 (1), 162-174, 2020
5742020
Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies
S Jain, JA Coulter, AR Hounsell, KT Butterworth, SJ McMahon, ...
International Journal of Radiation Oncology* Biology* Physics 79 (2), 531-539, 2011
5552011
Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles
SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ...
Scientific reports 1 (1), 18, 2011
4622011
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised …
DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw, W Chu, D Ford, ...
The Lancet Oncology 20 (11), 1531-1543, 2019
4452019
Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology clinical practice guideline endorsement
RC Chen, RB Rumble, DA Loblaw, A Finelli, B Ehdaie, MR Cooperberg, ...
Journal of Clinical Oncology 34 (18), 2182-2190, 2016
4112016
Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy
KT Butterworth, JA Coulter, S Jain, J Forker, SJ McMahon, G Schettino, ...
Nanotechnology 21 (29), 295101, 2010
3062010
Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance
S Malhotra, RS Karan, P Pandhi, S Jain
Postgraduate medical journal 77 (913), 703-707, 2001
2802001
UK consensus on normal tissue dose constraints for stereotactic radiotherapy
GG Hanna, L Murray, R Patel, S Jain, KL Aitken, KN Franks, N Van As, ...
Clinical Oncology 30 (1), 5-14, 2018
2492018
Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy
SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ...
Radiotherapy and Oncology 100 (3), 412-416, 2011
2382011
Genomics of lethal prostate cancer at diagnosis and castration resistance
J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ...
The Journal of clinical investigation 130 (4), 1743-1751, 2020
2352020
Radiotherapy in the presence of contrast agents: a general figure of merit and its application to gold nanoparticles
SJ McMahon, MH Mendenhall, S Jain, F Currell
Physics in Medicine & Biology 53 (20), 5635, 2008
2312008
Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles
JA Coulter, S Jain, KT Butterworth, LE Taggart, GR Dickson, SJ McMahon, ...
International journal of nanomedicine, 2673-2685, 2012
2182012
Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience
HB Musunuru, T Yamamoto, L Klotz, G Ghanem, A Mamedov, ...
The Journal of urology 196 (6), 1651-1658, 2016
2072016
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes
A Loblaw, P Cheung, L D’Alimonte, A Deabreu, A Mamedov, L Zhang, ...
Radiotherapy and Oncology 107 (2), 153-158, 2013
1822013
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non …
AC Tree, P Ostler, H van der Voet, W Chu, A Loblaw, D Ford, S Tolan, ...
The Lancet Oncology 23 (10), 1308-1320, 2022
1632022
Optimum imaging strategies for advanced prostate cancer: ASCO guideline
EJ Trabulsi, RB Rumble, H Jadvar, T Hope, M Pomper, B Turkbey, ...
Journal of Clinical Oncology 38 (17), 1963-1996, 2020
1572020
Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review
L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ...
European urology 77 (5), 614-627, 2020
1472020
The system can't perform the operation now. Try again later.
Articles 1–20